TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Suspected acute appendicitis on clinical and radiographic (CT) grounds~Exclusion Criteria:~1. Phlegmon, mass, peri-appendicecal abscess, or diffuse peritonitis~2. Prior open laparotomy with incision through the umbilicus~3. Body Mass Index \> 35~4. Age \<18 years~5. Mental illness, dementia, or inability to provide informed consent~6. Chronic pain requiring daily medication (including opiate and NSAIDs)~7. Pregnancy~8. Alternative diagnosis found by diagnostic laparoscopy (post-randomization)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SILS appendectomy (Type: EXPERIMENTAL): The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
- Conventional laparoscopic appendectomy (Type: ACTIVE_COMPARATOR): The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Assess the Association Between Human Bioimpedance Measurements and Clinical Urodynamic Procedures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients that have been previously scheduled for a Urodynamic Study~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- One single trial (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Outreach-ER: A Dementia Care Intervention Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* PLWD with a recent Emergency department visit or admission at Regions Hospital~* Diagnosis of dementia based on international classification of diseases (ICD) Codes in the medical record~* Provides informed consent prior to participation~* Must be able to read and speak English~* PLWD Living at Home~* Age \>=18 years for PLWD and their care partner~Exclusion Criteria:~* PLWD living in a nursing home/Long term care - Assisted living facility~* Current involvement in another clinical research study/trial for care partners~* PLWD medical record number (MRN) on the HealthPartners (HP) exclusion list

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Outreach-ER (Type: None): Outreach-ER is a psychosocial intervention designed by dementia experts in the field of care partner interventions. The care plan will be personalized to the needs of the care partner/PLWD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pain Level Reduction After Low-dose Radiation in Symptomatic Facet Joint Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with degenerative symptomatic facet joint osteoarthritis confirmed by MRI (lumbar spine) and standing X-ray~* Patients who underwent treatment for facet joint syndrome at the Dept. of Orthopaedic Surgery and Traumatology of KSA (Kantonsspital Aarau) or Dept. of Rheumatology of KSA or Dept. of Neurosurgery of KSA, onset of symptoms and treatment with pain medication and physiotherapy~* The informed consent form for participation in the study was signed~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Age ≥ 45 years~* Karnofsky Performance Status (KPS) ≥ 80 %~* Ability to take steroids and bridge or pause NOAC (New oral anticoagulants) / Marcoumar~* Show a positive Tracer-Uptake in the SPECT-CT in max. 4 facet joints of the lumbar spine (regardless of radiologic changes in MRI or CT)~* Immediate ≥ 70% pain reduction after 1 positive diagnostic infiltration of the suspected facet joint(s)~* Negative middle-/long-term effect (4-12 weeks after first steroid injection, defined as NRS 5-10 at 4-12 weeks)~Exclusion Criteria:~* Any previous infiltration therapy in the suspected spine region (+/- 3 segments) within the last 3 years~* Any previous radiotherapy, radiofrequency ablation, other pain modulating interventions (e.g. thermos/-cryoablation or spinal cord stimulators) or surgery in the suspected spine region (+/- 3 segments)~* Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except: nonmelanoma skin cancer, cervix carcinoma in situ, prostatic intraepithelial neoplasia) Contraindications to radiotherapy (for example connective tissue disorders such as scleroderma)~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Pregnancy, desire to have own children or lactation during study participation.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-articular steroid injections (Type: ACTIVE_COMPARATOR): The intra-articular steroid injections are the most common standard of care to treat the lower back pain resulting from FJA.
- Low-dose radiation therapy (Type: EXPERIMENTAL): LDRT is commonly used as treatment for benign degenerative inflammatory disorders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pancreatic Stump Closure After Distal Pancreatic Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patiens which the distal pancreatic resektions~* the type of resections that is techically possible with finnish binding panceatico-jejunal anastomosis~Exclusion Criteria:~* if the pancreas is not suitable for this kind of anastomosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- pancreatico-jejunal anastomosis (Type: ACTIVE_COMPARATOR): patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
- traditional anastomosis (Type: ACTIVE_COMPARATOR): pancreatic resections with traditional stump closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women~* Ages 18-65~* Meet Rome III criteria for functional dyspepsia~* Endoscopy within 1 year~Exclusion Criteria:~* Allergic reaction or history of adverse events with Nortriptyline or tricyclic antidepressants~* Organic cause found on physical examination~* Organic cause found on lab work: Complete Blood Count, Comprehensive Metabolic Panel, Thyroid stimulating hormone, Tissue transglutaminase Immunoglobulin A~* Predominantly Gastroesophageal reflux symptoms~* Current Helicobacter pylori infection~* History of Peptic ulcer disease~* Non steroidal antiinflammatory use use \> 2x/wk~* Pregnant or planning pregnancy~* History of major depression~* Abdominal surgery in the last year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nortriptyline (Type: ACTIVE_COMPARATOR): Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
- Sugar pill (Type: PLACEBO_COMPARATOR): Patients in this group will receive an identical placebo capsule at night for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 40~* In stable health~* Speak, read, understand English language~* If female, must be non-lactating and not pregnant~Exclusion Criteria:~* Heat pain detection thresholds above 47 ºC/116.6 ºF~* Inability to develop secondary hyperalgesia from the heat and capsaicin stimulation performed at the screening visit~* Serious psychiatric psychopathology (psychotic disorder, substance abuse)~* Tattoos in the area of measurements~* Allergy to study drugs (nalbuphine, naloxone, or capsaicin)~* Current or recent use opioids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Women (Type: EXPERIMENTAL): Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
- Men (Type: EXPERIMENTAL): Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and a positive culture or diagnosed by polymerase chain reaction (PCR) methods or by intradermal skin testing (Montenegro test).~* Number of lesions: 1 to 3 ulcerative lesions.~* Lesion´s diameter: 1 to 5 cm.~* Disease duration: up to three months.~Exclusion Criteria:~* Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)~* Immunodeficiency or antibody to HIV~* Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant disease, severe malaria, HIV, or other major infectious diseases~* Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months~  * Lack of suitability for the trial:~* Negative parasitology (aspirate/biopsy/PCR)or negative Montenegro test~* Any history of prior anti-leishmania therapy~* Any condition which compromises ability to comply with the study procedures~  * Administrative reasons:~* Lack of ability or willingness to give informed consent (patient and/or parent / legal representative)~* Anticipated non-availability for study visits/procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fluconazole (Type: EXPERIMENTAL): Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
- Meglumine Antimoniate (Type: ACTIVE_COMPARATOR): Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6.0 to \<46.0 years~* Diagnosis of type 1 diabetes with initiation of insulin therapy within past 7 days (day 1 being the first day of insulin therapy)~* If participant is female with reproductive potential, willing to avoid pregnancy and pregnancy test negative.~* Willing to accept randomization to either the intensive diabetes management group or the standard care group.~* Willing to complete the planned 2 years of follow-up.~* Able to electronically transmit data monthly.~* Investigator believes that the participant (and parent/guardian for children) understands and agrees to comply with the study protocol and is capable of undertaking all necessary testing.~Exclusion Criteria:~* Currently pregnant or lactating, or anticipate getting pregnant in the next one year.~* Currently anemic (hematocrit level will be obtained at the screening visit).~* Chronic use of systemic steroids or other noninsulin pharmaceuticals that might affect glycemic control or the presence of a disease that is likely to be treated with such medications during the first two years of the study.~* Complicating medical issues that might interfere with study conduct.~* Inpatient psychiatric treatment in the past 6 months (if the participant is a minor, for either the participant or the participant's primary care giver).~* Currently participating in another type 1 diabetes treatment study, including an intervention trial for treatment of diabetic ketoacidosis.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Intensive Treatment (Type: EXPERIMENTAL): closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
- Standard Treatment (Type: ACTIVE_COMPARATOR): home glucose monitoring (2 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cortico-saving Treatments Proposed for CLIPPERS: a First Cohort

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient correctly informed about the study~* Symptoms and/or clinical signs indicating that the brain stem is affected~* MRI shows punctate gadolinium highlights and/or curvilinear bridge and/or middle cerebellar peduncles~* Clinical and radiological cortico sensitivity~* If a cerebral biopsy has been performed, presence of a lymphocytic, histiocytic or lympho-hysticytic infiltrate~Exclusion Criteria:~* symptoms and/or clinical signs indicating impairment other than the central nervous system~* Cortical impairment present on MRI, microbleeds, stenosis on magnetic resonance angiography, or pacchymeningitis~* Presence of other diseases that could explain such clinical and radiological signs (see inclusion criteria)~* If a cerebral biopsy has been performed, presence of signs of malignancy (eg, clonal proliferation, cellular atypia), vasculitis, granuloma, or demyelination

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLIPPERS patients (Type: None): The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Pandemic Stress Vaccine: A Resource to Enhance the Resilience of Healthcare Workers Facing an Infectious Outbreak

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* employee or professional staff of a hospital~Exclusion Criteria:~* unable to read and write English

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pandemic Stress Vaccine - Interactive (Type: EXPERIMENTAL): None
- Pandemic Stress Vaccine - Didactic (Type: ACTIVE_COMPARATOR): None
- Wait list (Type: NO_INTERVENTION): Some participants are assigned to an eight week waiting condition prior to the course commencing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cancer End Of Life Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Palliative advanced cancer patient (Palliative chemotherapy, analgesic radiotherapy, surgery of comfort accepted).~* All cancer locations and cancer type~* Patient having the knowledge of their palliative disease stage.~* Patient follow-up at least once a month by a palliative caregiver.~* Age \> or = 18 years.~* Dated and signed consent.~* PS \> or = 2~* Life expectation \> or = 1 month.~Exclusion Criteria:~* Psychiatric Disease or cognitive disorders disrupting the trial understanding and the enlightened and voluntary consent character.~* Patient who can not submit itself to the formal follow-up for psychological, social, family or geographical reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death
- Arm B (Type: EXPERIMENTAL): Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death
- Arm C (Type: EXPERIMENTAL): Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death
- Arm D (Type: EXPERIMENTAL): Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage II, III, or IV high-grade non-Hodgkin's lymphoma that has not responded to, or has relapsed after a standard primary chemotherapy regimen plus at least 1 standard second-line salvage chemotherapy regimen NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adoptedby PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC greater than 2000/mm\^3~* Platelet count greater than 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of cardiovascular conditions that contraindicate high dosages of sodium~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infection requiring treatment~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agent (e.g., interferon or interleukin-2)~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agent~Endocrine therapy:~* At least 4 weeks since prior dexamethasone, prednisone, or other corticosteroids~* No concurrent corticosteroid~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* No prior antineoplaston therapy~* No concurrent antibiotics, antifungals, or antivirals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues